Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

References

• 1. Litchfield K, Reading JL, Puttick C et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184(3), 596–614; e514 (2021).
  Medline CASGoogle Scholar
• 2. Mcgrail DJ, Pilie PG, Rashid NU et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32(5), 661–672 (2021).
  Medline CASGoogle Scholar
• 3. De Bortoli T, Benary M, Horak P et al. Tumour mutational burden and survival with molecularly matched therapy. Eur. J. Cancer 190, 112925 (2023).
  MedlineGoogle Scholar
• 4. Offin M, Rizvi H, Tenet M et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 25(3), 1063–1069 (2019).
  Medline CASGoogle Scholar
• 5. Lin C, Shi X, Zhao J et al. Tumor mutation burden correlates with efficacy of chemotherapy/targeted therapy in advanced non-small cell lung cancer. Front Oncol. 10, 480 (2020).
  Medline CASGoogle Scholar
• 6. Smith AE, Ferraro E, Safonov A et al. HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat. Commun. 12(1), 6667 (2021).
  Medline CASGoogle Scholar
• 7. Hyman DM, Piha-Paul SA, Won H et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554(7691), 189–194 (2018).
  Medline CASGoogle Scholar
• 8. Taber A, Christensen E, Lamy P et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11(1), 4858 (2020).
  Medline CASGoogle Scholar
• 9. Lengel HB, Mastrogiacomo B, Connolly JG et al. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 41(5), 970–985; e973 (2023).
  Medline CASGoogle Scholar
• 10. Tsang ES, Csizmok V, Williamson LM et al. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. NPJ Precis. Oncol. 7(1), 31 (2023).
  Medline CASGoogle Scholar
• 11. Batalini F, Gulhan DC, Mao V et al. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin. Cancer Res. 28(21), 4714–4723 (2022).
  Medline CASGoogle Scholar
• 12. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 12(1), 31–46 (2022).
  Medline CASGoogle Scholar
• 13. Neyret-Kahn H, Fontugne J, Meng XY et al. Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks. Oncogene 42(19), 1524–1542 (2023).
  Medline CASGoogle Scholar
• 14. Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22(6), 323–339 (2022).
  Medline CASGoogle Scholar
• 15. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29(24), 3316–3321 (2011).
  Medline CASGoogle Scholar